ABSTRACT Genome-wide association studies (GWAS) identified novel genes associated with type 2 diabetes mellitus (T2DM) which have been replicated in different ethnic populations and yielded inconsistent results. The insulin-like growth factor mRNA-2 binding protein 2 (IGF2BP2) is highly expressed in pancreatic islets, which play roles in normal embryonic growth and development. Our study aimed to replicate the association between insulin growth factor 2 mRNA binding protein 2 (IGF2BP2) gene (rs4402960) variant and T2DM in Egyptian diabetic patients resident in Ismailia city. The study included 152 subjects (76 unrelated T2DM patients and 76 control subjects) who were genotyped by polymerase chain reaction-restriction fragment length polymorphism technique (PCR-RFLP). Age, sex, blood pressure, BMI and Waist Circumference were recorded, and blood glucose, serum triglyceride, total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) and homeostatic model assessment (HOMA) indices were determined. Fasting serum insulin and IGF2BP2 protein levels were analyzed by ELISA. For rs440960 variant of IGF2BP2 gene, risk allele T frequency was associated with T2DM [OR (95% CI)=1.82 (1.14-2.93), P= 0.012]. The frequency of T/T genotype versus (GG+G/T) genotypes was significantly higher in T2DM patients compared to controls (22.4% vs. 77.6% and 5.3% vs. 94.7%, respectively), (P=0.002). This association remained significant under additive (P=0.003) and co-dominant (P=0.009) genetic models. From this study, it could be concluded that IGF2BP2 rs4402960 polymorphism was found to be significantly associated with the 
INTRODUCTION
Diabetes mellitus is a worldwide medical issue with a an enormous effect on morbidity and premature mortality worldwide. The estimated global prevalence of diabetes among adults (aged 20-79 years old) will be 8.8%, influencing 425 million adults in 2017 and will increment to 9.9 %, and 629 million adults by the 2045 (International Diabetes Federation, 2017). T2DM is a disease characterized by high blood glucose levels as a result of a pancreatic β-cell dysfunction, impaired insulin secretion and insulin resistance and is caused by the perplexing interaction between genetic, epigenetic, and environmental factors. T2DM is a complex metabolic syndrome with a strong genetic components play a role in the pathogenesis of T2DM ( The IGF2BP2 gene variants are arranged on the chromosome (3q27.2). The intron 2 is the location of (rs44020960) and (rs1470579) SNPs, which have been observed to be related to an increased risk for T2DM (Chistiakov et al., 2012). IGF2BP2 has seen to be identified with decreased insulin secretion, which assumes a part of T2DM. IGF2BP2 gene variant may end up impacting the levels of IGF2 in β-cells. IGF2 overexpression induces β-cell dysfunction and increases β-cell susceptibility to damage (Casellas et al., 2015). In this study, we intended to evaluate the presence of IGF2BP2 gene polymorphism and to assess whether it associated with T2DM risk in Egyptian patients resident in Ismailia city.
MATERIALS AND METHODS
This case-control study included 152 subjects, (76 unrelated T2DM patients and 76 healthy control subjects). The T2DM patients were recruited from the diabetes clinic at Suez Canal University Hospital, The following equations were used: HOMA-IR = (fasting insulin (μU/ml) x Fasting blood glucose (mmol/l) / 22.5, HOMA-β% = (20x fasting insulin (μU/ml))/ Fasting blood glucose (mmol/l) ( Matthews et al.,1985) . Genotyping of IGF2BP2 SNP(rs4402960) Genomic DNA was purified from whole blood by using a QIAamp DNA Blood Mini Kit (Qiagen, UK) according to manufacturer's protocol. Genotypes for the IGF2BP2 rs4402960 polymorphism were analyzed using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. All primers designed by
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Biosearch Technologies Inc (USA). The primers sequence were Forward5'-AGACCAGCCTTGGCAATGTAGTG-3'and reverse5'CTAAAGCACTGAGAGAAACAGCCCT-3'. DNA was initially denatured at 95•C for 5 min prior to amplification. then 30 cycles, consisting of 2 min denaturation at 95•C, 45 sec annealing at 62•C, and 1 min extension at 72•C and the final extension for 1 min at 72•C. Restriction digestion was performed in a total volume of 10 μl amplicons, 1μl NE buffer and 8 units of Mbo II enzyme (New England Bio-labs, Beverly, Mass, USA). Samples were then incubated for 5 hrs at 37•C and the digested PCR products were separated by 2.0% agarose gel electrophoresis. Thus, the following genotypes were identified by bands of the following sizes; GG ( 
Clinical and biochemical characteristics of the studied subjects:
The clinical and biochemical characteristics of studied subjects were summarized in Table ( Tables (2 and 3 ). (TT vs. GG) Figure 1 . Agarose gel electrophoresis of restriction digests of PCR products of IGF2BP2 gene using MboII restriction enzyme on 2%(w/v) agarose gel. M:50 bp Marker, lanes 3, 5 and 8 are GG genotypes, lanes 1, 6 and 7are GT genotypes and lanes 2 and 4 are TT genotypes for T2DM patients. Lanes11, 14 and 15 are GG genotypes, lanes 9, 10, 12 and 13 are GT genotypes for controls.
, recessive model (TT vs. GG+GT), dominant model (GG vs. +GT+ TT), and co-dominant model (GG vs. GT vs. TT).
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DISCUSSION
The IGF2BP2 is one of the genes identified through GWAS to be associated with T2DM, which has been repeatedly confirmed among different ethnic populations (Zeggini et al., 2007) , many studies confirmed the association of (rs4402960) SNP of IGF2BP2 gene with T2DM, but other studies reported no association between this SNP ., 2015) . The results of the current study were in contrast to those reported by Ibrahim et al. (2016) who found that no association of (rs4402960) The insignificant associations found in other ethnic populations could be explained by study design, sample size or the limited number of studies which had insufficient statistical power to detect a slight effect (Han et al., 2010) . Also, some studies have examined several genetic models (Nemr et al., 2012) , while other studies have examined only the additive model (Hertel et al., 2008) . The present study revealed that (GT+TT) genotypes of (rs4402960) variant of IGF2BP2 gene carriers of diabetic patients showed significantly higher fasting plasma glucose levels as compared with carriers of GG genotype. Zhang et al. (2014) reported that T2DM patients with the T allele had higher FPG (P<0.01) and 2-h PPG (P<0.05) levels than those with the GG genotype. In our study, the diabetic patients who carried (GT+TT) genotype of IGF2BP2 SNP (rs4402960) were associated with significant reduction of homeostatic model assessment of β-cell function (HOMA-β%) compared with carriers of GG genotype. The association of this SNP
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with HOMA-β reduction suggested that IGF2BP2 gene variant (rs4402960) confers T2DM risk through a reduction of β-cell function (Huang et al., 2010) . Our data revealed significant elevation of serum IGF2BP2 protein in diabetic patients compared to control subjects (P<0.05). The high level of IGF2BP2 protein suggested that up-regulation of IGF2BP2 in T2DM could influence insulin-like growth factor 2 (IGF2) levels, as IGF2BP2 binds to the 5′-UTR of the IGF2 mRNAs, influencing the protein levels (Dai et al., 2011) . IGF2 overexpression in islets leads to islet dysfunction and makes them more vulnerable to β-cell damage and immune attack in mice (Casellas et al., 2015) . The exact biological role of IGF2BP2 in the pathogenesis of T2DM is not well elucidated, multiple studies have suggested that IGF2BP2 polymorphisms were associated with an impaired pancreatic β-cell function (Zeggini et al., 2007) . Interactions between genetic variation in IGF2BP2 and T2DM may be exerted through the IGF2 pathway and through the insulin pathway. In addition, IGF2BP2 has been demonstrated to affect first-phase insulin secretion and the disposition index during hyperglycemic clamps. It is possible that IGF2BP2 would reduce the size or number of β-cells by sequestering IGF2 mRNA in these cells, resulting in a reduced insulin secretion (Rodriguez et al., 2010 ). In conclusion, In this study, we validated that the IGF2BP2 polymorphism (rs4402960) may be associated with the development of T2DM and the IGF2BP2 may be a susceptibility gene for T2DM in Egyptian population resident in Ismailia city.
